Can a Cholesterol-Lowering injection help lung cancer patients stay on a key treatment?
NCT ID NCT07674368
First seen Jun 29, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This study tests whether recakimab, an injectable drug that lowers cholesterol, can safely reduce high cholesterol caused by the lung cancer medication lorlatinib. The trial enrolls about 29 adults with advanced ALK-positive non-small cell lung cancer who developed high cholesterol while taking lorlatinib. Participants receive recakimab injections every 8 weeks for up to 32 weeks, and researchers track changes in cholesterol levels and any side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Recakimab (a PCSK9 inhibitor injection)
- What this could lead to
- If it works, this could offer a way to manage a common side effect of a key lung cancer treatment, potentially allowing more people to stay on lorlatinib longer.
- What could go wrong
- This is a small, early-phase study with only 29 participants and no comparison group, so results may not apply broadly. The cholesterol-lowering effect may be modest or not sustained.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China